Abstract
This study evaluated the pharmacological activity of PTX3, administered in combination with voriconazole, in a rat model of pulmonary aspergillosis. The data indicated additive therapeutic activities of these compounds, as demonstrated by the amelioration of respiratory function changes, reduction of lung fungal burden, and increased survival. Overall, we provide clear evidence that the combination of PTX3 with a suboptimal dose of voriconazole might represent a therapeutic option under those clinical conditions where the use of voriconazole alone is not warranted for efficacy and tolerability reasons.
MeSH terms
-
Animals
-
Antifungal Agents / therapeutic use*
-
Body Burden
-
C-Reactive Protein / therapeutic use*
-
Colony Count, Microbial
-
Cortisone / pharmacology
-
Drug Combinations
-
Galactose / analogs & derivatives
-
Immunosuppressive Agents / pharmacology
-
Kaplan-Meier Estimate
-
Lung / microbiology
-
Mannans / metabolism
-
Organ Size
-
Pulmonary Aspergillosis / drug therapy*
-
Pulmonary Aspergillosis / microbiology
-
Pyrimidines / therapeutic use*
-
Rats
-
Respiratory Function Tests
-
Serum Amyloid P-Component / therapeutic use*
-
Survival
-
Triazoles / therapeutic use*
-
Voriconazole
Substances
-
Antifungal Agents
-
Drug Combinations
-
Immunosuppressive Agents
-
Mannans
-
Pyrimidines
-
Serum Amyloid P-Component
-
Triazoles
-
galactomannan
-
PTX3 protein
-
C-Reactive Protein
-
Voriconazole
-
Cortisone
-
Galactose